152 related articles for article (PubMed ID: 3883504)
1. Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.
Anderson G; Payne H
Semin Oncol; 1985 Mar; 12(1 Suppl 2):21-2. PubMed ID: 3883504
[TBL] [Abstract][Full Text] [Related]
2. [A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].
Kado M; Oshima S; Matsui Y; Shimokata K; Hara K; Kanda T; Shima K; Takenaka S
Gan To Kagaku Ryoho; 1986 Jan; 13(1):116-21. PubMed ID: 3002282
[TBL] [Abstract][Full Text] [Related]
3. [A phase II study of NK171 (etoposide)].
Kimura K; Niitani H
Gan To Kagaku Ryoho; 1985 Oct; 12(10):2011-7. PubMed ID: 2996442
[TBL] [Abstract][Full Text] [Related]
4. [A phase II study of oral VP-16 in primary lung cancer].
Matsui Y; Ohshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1801-7. PubMed ID: 2994576
[TBL] [Abstract][Full Text] [Related]
5. [Chemotherapy of non-small-cell bronchial cancer with a combination of Cis-diamminedichloroplatinum (II) and VP 16-213].
Joss R; Goldhirsch A; Cavalli F; Weber W; Kaplan S; Obrecht JP; Sonntag R; Brunner KW
Schweiz Med Wochenschr; 1981 Sep; 111(36):1331-4. PubMed ID: 7197802
[TBL] [Abstract][Full Text] [Related]
6. Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial.
Wolff SN; Birch R; Sarma P; Greco FA
Cancer Treat Rep; 1986 May; 70(5):583-7. PubMed ID: 3011257
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study.
Gridelli C; Rossi A; Scognamiglio F; Guida C; Fiore F; Gatani T; Scoppa G; Pergola M
Anticancer Res; 1997; 17(6D):4755-8. PubMed ID: 9494602
[TBL] [Abstract][Full Text] [Related]
8. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
9. [A phase II study of etoposide (NK 171) in small cell lung cancer--comparison of results between intravenous administration and oral administration].
Furuse K
Gan To Kagaku Ryoho; 1985 Dec; 12(12):2352-7. PubMed ID: 3000299
[TBL] [Abstract][Full Text] [Related]
10. VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.
Eagan RT; Ingle JN; Creagan ET; Frytak S; Kvols LK; Rubin J; McMachon RT
Cancer Treat Rep; 1978 May; 62(5):843-4. PubMed ID: 657168
[No Abstract] [Full Text] [Related]
11. [VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].
Ryssel HJ; Hasler E; Sonntag RW; Cavalli F; Martin J; Tschopp L; Brunner KW
Schweiz Med Wochenschr; 1977 Jul; 107(26):912-5. PubMed ID: 877537
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of VP-16-213 in non-small-cell lung cancer.
Itri LM; Gralla RJ; Chapman RA; Kelsen DP; Casper ES; Golbey RB
Am J Clin Oncol; 1982 Feb; 5(1):45-7. PubMed ID: 7081137
[TBL] [Abstract][Full Text] [Related]
13. Etoposide by oral route in the treatment of unresectable non-small cell lung cancer.
Scagliotti G; Lodico D; Gozzelino F; Pescetti G
Chemioterapia; 1984 Oct; 3(5):324-6. PubMed ID: 6532545
[TBL] [Abstract][Full Text] [Related]
14. [Effects of oral etoposide in small cell carcinoma of the lung].
Miyamoto H; Ito M; Araya Y; Takaoka K; Isobe H; Dosaka H; Kawakami Y; Shimizu T; Onodera S
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1244-7. PubMed ID: 6329103
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma.
Konits PH; Van Echo DA; Aisner J; Morris D; Wiernik PH
Am J Clin Oncol; 1982 Oct; 5(5):515-9. PubMed ID: 6758569
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers.
Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK
Cancer Treat Rep; 1981; 65(5-6):453-8. PubMed ID: 6263477
[TBL] [Abstract][Full Text] [Related]
17. High-dose etoposide with autologous bone marrow transplantation as initial treatment of small cell lung cancer--a negative report.
Littlewood TJ; Bentley DP; Smith AP
Eur J Respir Dis; 1986 May; 68(5):370-4. PubMed ID: 3015650
[TBL] [Abstract][Full Text] [Related]
18. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.
Cavalli F; Sonntag RW; Jungi F; Senn HJ; Brunner KW
Cancer Treat Rep; 1978 Mar; 62(3):473-5. PubMed ID: 348319
[No Abstract] [Full Text] [Related]
19. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Radice PA; Bunn PA; Ihde DC
Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
[No Abstract] [Full Text] [Related]
[Next] [New Search]